FY2024 EPS Estimates for electroCore Cut by Analyst

electroCore, Inc. (NASDAQ:ECOR) – Analysts at Brookline Capital Management reduced their FY2024 earnings per share (EPS) estimates for shares of electroCore in a research report issued to clients and investors on Thursday, November 14th. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($1.40) per share for the year, down from their prior forecast of ($1.03). The consensus estimate for electroCore’s current full-year earnings is ($1.44) per share. Brookline Capital Management also issued estimates for electroCore’s Q4 2024 earnings at ($0.33) EPS.

electroCore Price Performance

electroCore stock opened at $10.94 on Monday. electroCore has a fifty-two week low of $5.02 and a fifty-two week high of $14.20. The firm has a market capitalization of $71.66 million, a PE ratio of -5.98 and a beta of 0.56. The company’s 50-day moving average is $8.89 and its 200-day moving average is $7.23.

Institutional Investors Weigh In On electroCore

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock worth $458,000 after buying an additional 5,951 shares during the period. HighTower Advisors LLC bought a new position in shares of electroCore during the third quarter worth approximately $255,000. International Assets Investment Management LLC boosted its stake in electroCore by 689.1% in the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock valued at $3,864,000 after purchasing an additional 467,326 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after buying an additional 2,270 shares in the last quarter. Institutional investors own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.